Results 211 to 220 of about 1,426,705 (304)

Breast Cancer and Ovarian Tissue Cryopreservation: SWOT Analysis. [PDF]

J Clin Med
Raimondo D, Doglioli M, Forastiere C, Vicenti R, Schirripa M, Pazzaglia E, Miscia M, Neola D, Bertoldo L, Massucci M, Serra M, Cobellis L, Seracchioli R, Raffone A.   +13 more
europepmc   +1 more source

Tumbling Magnetic Microrobots for Targeted In Vivo Drug Delivery in the GI Tract

Advanced Robotics Research, EarlyView.
We introduce a microrobot design and integrated system for on‐demand targeted drug release in the gastrointestinal tract. The microrobot has an embedded magnet for actuation with external magnetic fields and is visualized in real time using ultrasound. It has two drug release ports sealed with a thermally sensitive wax. Local heating of the wax using a
Aaron C. Davis, Luis Carlos Sanjuan Acosta, Shubh P. Mehta, Baiyan Qi, Yang Yang, Luis Solorio, Craig J. Goergen, David J. Cappelleri   +7 more
wiley   +1 more source

Real-world evidence of mammography screening from the Hong Kong Breast Cancer Registry: a cost minimisation analysis of 15 144 patients with breast cancer. [PDF]

BMJ Public Health
Hao Z, Lam A, Hu Y, Lee C, Yeo W, Kwok C, Soong I, Ng TY, Chiu J, Chan M, Chan S, Wong TT, Li L, Hung WK, Yip B, Yiu K, Yau CC, Cheung P, Tsoi KKF.   +18 more
europepmc   +1 more source

Interactions of Antibody Drug Conjugate Anti‐Tubulin and Topoisomerase I Inhibitor Payloads with Radiotherapy to Potentiate Immunotherapy

Advanced Science, EarlyView.
Antibody drug conjugates deliver their cytotoxic anti‐tubulin or topoisomerase I inhibitor payloads to tumors through cancer cell receptor targeting. The released drug payloads induce cellular changes that interact with radiotherapy resulting in radiosensitization that improves cancer cell kill and stimulates anti‐tumor immune responses.
Jacqueline Lesperance, Bryan S. Yung, Michael M. Allevato, Marcus M Cheng, Maria F. Camargo, Robert Saddawi‐Konefka, Kanika Dhawan, Ashwyn K. Sharma, Mahsa Mortaja, Sophie Bice, Daniel J. Scanderbeg, Diego Alvarado, Jyoti Mayadev, Ramez N. Eskander, Stephen R. Adams, Pippa F. Cosper, J. Silvio Gutkind, Sunil J. Advani   +17 more
wiley   +1 more source

The Role of Irisin and Physical Activity in Breast Cancer. [PDF]

In Vivo
Wiatr M, Partyńska A, Dzięgiel P, Woźniewski M.   +3 more
europepmc   +1 more source

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

Advanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao, Qinyuan Liu, Zhongwei Xin, Zhiyao Zhou, Mingjie Lin, Di Chen, Zhixing Hao, Yongyuan Chen, Wenxuan Wu, Shuyang Zhang, Xiaoke Chen, Xia Xu, Jinfan Li, Wei Lin, Yuhao Lu, Dang Wu, Pin Wu   +16 more
wiley   +1 more source

The Role of Selected Bacteria in Breast Cancer Initiation and Development. [PDF]

Int J Mol Sci
Gebretsadik G, Islam S, Szpendyk J, Thomas V, Furuta S.   +4 more
europepmc   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source